What was the overall market valuation of the UK prostate cancer market in 2024?

The overall market valuation was $485.38 Million in 2024. Read More

What is the projected market valuation for the UK prostate cancer market by 2035?

The projected valuation for 2035 is $1,087.56 Million. Read More

What is the expected CAGR for the UK prostate cancer market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 7.61%. Read More

Which companies are considered key players in the UK prostate cancer market?

Key players include AbbVie Inc, Bristol-Myers Squibb Company, Johnson & Johnson, Astellas Pharma Inc, Merck & Co Inc, Novartis AG, Pfizer Inc, Sanofi S.A., and Amgen Inc. Read More

What are the two main types of prostate cancer segments in the market?

The two main types are Prostatic Adenocarcinoma, valued between $350.0 Million and $800.0 Million, and Small Cell Carcinoma, valued between $135.38 Million and $287.56 Million. Read More

What are the two primary components of the UK prostate cancer market?

The primary components are Therapy, valued between $350.0 Million and $800.0 Million, and Diagnosis, valued between $135.38 Million and $287.56 Million. Read More

Which end users dominate the UK prostate cancer market?

The dominant end users are Specialty Centers, valued between $121.07 Million and $267.56 Million, and Hospitals & Clinics, valued between $364.31 Million and $820.0 Million. Read More

How does the market valuation for Therapy compare to that for Diagnosis?

Therapy has a higher valuation, ranging from $350.0 Million to $800.0 Million, compared to Diagnosis, which ranges from $135.38 Million to $287.56 Million. Read More

What is the significance of the projected growth in the UK prostate cancer market?

The projected growth indicates a robust market expansion, with an increase from $485.38 Million in 2024 to $1,087.56 Million by 2035. Read More

How do the valuations of Specialty Centers and Hospitals & Clinics compare?

Hospitals & Clinics have a higher valuation, ranging from $364.31 Million to $820.0 Million, compared to Specialty Centers, which range from $121.07 Million to $267.56 Million. Read More

UK Prostate Cancer Market

UK Prostate Cancer Market Research Report: Size, Share, Trend Analysis By Types (Prostate Adenocarcinoma, Small Cell Carcinoma), By Component (Therapy, Diagnosis) and By End-User (Specialty Centers, Hospital & Clinics) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.61%

2024 Market Size

$ 485.38 Million

2035 Market Size

$ 1,087.56 Million

Medical Device ● Updated February 2026 Report ID: MRFR/MED/54354-HCR | Pages: 200 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Million)
  1. 4.1.1 Prostatic Adenocarcinoma
  2. 4.1.2 Small Cell Carcinoma
2. 4.2 Healthcare, BY Component (USD Million)
  1. 4.2.1 Therapy
  2. 4.2.2 Diagnosis
3. 4.3 Healthcare, BY End User (USD Million)
  1. 4.3.1 Specialty Centers
  2. 4.3.2 Hospital & Clinics
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Astellas Pharma Inc (JP)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi S.A. (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen Inc (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY TYPE
3. 6.3 UK MARKET ANALYSIS BY COMPONENT
4. 6.4 UK MARKET ANALYSIS BY END USER
5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF HEALTHCARE
8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
11. 6.11 HEALTHCARE, BY TYPE, 2024 (% SHARE)
12. 6.12 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 HEALTHCARE, BY COMPONENT, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY COMPONENT, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY END USER, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY COMPONENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Prostate Cancer Market Segmentation

UK Prostate Cancer Market By Type (USD Million, 2025-2035)

Prostatic Adenocarcinoma
Small Cell Carcinoma

UK Prostate Cancer Market By Component (USD Million, 2025-2035)

Therapy
Diagnosis

UK Prostate Cancer Market By End User (USD Million, 2025-2035)

Specialty Centers
Hospital & Clinics

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”